GH 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-07-30

• Total revenue was $335.0 million for the three months ended June 30, 2026, compared to $232.1 million for the three months ended June 30, 2025, an increase of $102.9 million, or 44%.

• Oncology revenue was $219.1 million for the three months ended June 30, 2026, compared to $158.7 million for the three months ended June 30, 2025, an increase of $60.4 million, or 38%. This increase was driven primarily by an increase in oncology test volume to approximately 104,000 for the three mo…

• Biopharma and data revenue was $60.9 million for the three months ended June 30, 2026, compared to $56.0 million for the three months ended June 30, 2025, an increase of $4.9 million, or 9%. This increase was driven primarily by the achievement of certain milestones within our companion diagnostic d…

• Screening revenue was $52.9 million for the three months ended June 30, 2026, compared to $14.8 million for the three months ended June 30, 2025, an increase of $38.1 million, or 257%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 66,000 for th…

• Cost of revenue was $115.9 million for the three months ended June 30, 2026, compared to $81.2 million for the three months ended June 30, 2025, an increase of $34.7 million, or 43%. This increase in cost of revenue was driven primarily by an increase in sample volume, partially offset by reduced co…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• Comparison of the Three Months Ended March 31, 2026 and 2025

• Total revenue was $301.7 million for the three months ended March 31, 2026, compared to $203.5 million for the three months ended March 31, 2025, an increase of $98.2 million, or 48%.

• Oncology revenue was $205.0 million for the three months ended March 31, 2026, compared to $150.6 million for the three months ended March 31, 2025, an increase of $54.4 million, or 36%. This increase was driven primarily by an increase in oncology test volume to approximately 86,000 for the three m…

• Biopharma and data revenue was $53.0 million for the three months ended March 31, 2026, compared to $45.4 million for the three months ended March 31, 2025, an increase of $7.6 million, or 17%. This increase was driven primarily by the achievement of certain milestones within our companion diagnosti…

• Screening revenue was $41.6 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025, an increase of $35.9 million, or 633%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 44,000 for t…

相对上期新增的文字 · 来源:10-Q · 2026-07-30

• The majority of our revenue is generated in the United States. Through June 30, 2026, we have generated an insignificant amount of revenue denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly b…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• The majority of our revenue is generated in the United States. Through March 31, 2026, we have generated an insignificant amount of revenue denominated in foreign currencies. As we expand our presence in the international

• market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. As of March 31, 2026, the effect of a hypothetical 10% chan…

相对上期新增的文字 · 来源:10-Q · 2026-07-30

• (2)The 10b5-1 trading plan provides for the sale of 50% of an indeterminable number of shares of our common stock underlying certain restricted stock unit awards that will vest during the duration of the trading arrangement.